BIODiscovery New Zealand Ltd is a privately owned company based in Auckland and Wellington with additional staff represented in Napier.  BioDiscovery's objective is to extract value from New Zealand's biodiversity; the company's core activity is the discovery and development of beneficial plant-microbe associations.

BioDiscovery NZ Ltd was established in 1994 by three experienced research scientists resident in Auckland, New Zealand.  In 2001 the company expanded it's capability to include a fully equipped natural product chemistry facility in Wellington.  This facility enables it to provide clients with novel, purified compounds that are biologically active against specified insect, fungal or nematode targets.

BioDiscovery funds its growth solely from competitive government research contracts and from partnerships with domestic and international companies.  The company currently employs 15 full-time research staff (including 8 PhDs).  BioDiscovery is wholly owned by two of the founding scientists

 

Microbial Discovery

BioDiscovery has developed a world-leading capability in the discovery of beneficial plant-microbe associations and bioactive microbes for agriculture; this is evidenced by our collaborations and partnerships with some of the world's biggest agrochemical companies.

Through its proprietary high throughput technologies, the company is able to rapidly discover and characterise beneficial plant/microbe associations for a broad range of forage, row and tree crops.

BioDiscovery currently has a collection of >45,000 indigenous microbes each screened for bioactivity against a panel of 10 plant pests and diseases; this research is ongoing.

Central to BioDiscovery’s research approach is its ability to legitimately access the diverse ecosystems of New Zealand, one of the world's least exploited natural resources.

Contract Research

BioDiscovery operates contract research programmes and proprietary discovery programmes for microbial crop improvement and microbial natural products.  

The cost of research in New Zealand is low compared to that in the U.S. and Europe, yet the quality of the science is first-rate. Partners are therefore able to realise an excellent return on investment.